ACE2 and COVID-19: Earlier studies have demonstrated that the angiotensin‐converting enzyme 2 (ACE2) as a direct mediator regulates the SARS‐CoV‐2 entry into enterocytes in the gastrointestinal tract,62 and COVID‐19 patients often show gastrointestinal symptoms including vomiting, belly pain, and diarrhoea.63